BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company ...

The T7+ integrates MGI's proprietary DNBSEQ™ technology with next-generation fluidics, optics, and bioinformatics, creating a platform that is faster, smarter, and more versatile than ever before. The ...

Next-generation metagenomic sequencing test developed at UCSF proves its effectiveness in quickly diagnosing almost any kind of pathogen. A genomic test developed at UC San Francisco to rapidly detect ...

This study demonstrates that NGS-MSI is noninferior to IHC-MMR and can identify MSI-H tumors that IHC-MMR is unable to detect and conversely IHC-MMR can identify MMRd tumors that NGS-MSI misses. This ...

A genomic test developed at UC San Francisco to rapidly detect almost any kind of pathogen – virus, bacteria, fungus or parasite – has proved successful after a decade of use. The test has the ...

Bulk harvest release testing for adventitious viruses is an integral part of biosafety for manufacturing biopharma products. Finding a testing strategy that works for diverse biologics modalities ...

The webinar series titled "The Basics of Next Generation Sequencing and its Application in Precision Oncology" aims to provide a comprehensive understanding of the fundamentals and practical ...

“Watchmaker’s enzyme offers a combination of attributes that establish a new benchmark for reverse transcriptase performance,” says Sara Mann, VP of Commercial Excellence at Promega. “By incorporating ...

FORT DETRICK, Md. – Researchers at the U.S. Army Medical Research Institute of Infectious Diseases are testing a promising new biological threat detection method in high-fidelity training scenarios, ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.